Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation

In this pooled analysis of seven multicentre cohorts potential differences were investigated in the incidence, characteristics and outcomes between intracranial haemorrhages (ICHs) associated with the use of non‐vitamin K antagonist oral anticoagulants (NOAC‐ICH) or with vitamin K antagonists (VKA‐ICH) in ischaemic stroke patients after oral anticoagulant treatment initiation for atrial fibrillation (AF).

[1]  D. Werring,et al.  Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation , 2019, Annals of neurology.

[2]  S. Warach,et al.  Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation , 2019, The Lancet Neurology.

[3]  Sung-Chun Tang,et al.  Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[4]  A. Alexandrov,et al.  Clinical Outcomes and Neuroimaging Profiles in Nondisabled Patients With Anticoagulant-Related Intracerebral Hemorrhage , 2018, Stroke.

[5]  A. Alexandrov,et al.  Neuroimaging and clinical outcomes of oral anticoagulant–associated intracerebral hemorrhage , 2018, Annals of neurology.

[6]  A. Alexandrov,et al.  Fatal oral anticoagulant‐related intracranial hemorrhage: a systematic review and meta‐analysis , 2018, European journal of neurology.

[7]  S. Matsuda,et al.  Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin , 2018, Neurology.

[8]  Eric E. Smith,et al.  Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality , 2018, JAMA.

[9]  A. Alexandrov,et al.  Direct oral anticoagulant– vs vitamin K antagonist–related nontraumatic intracerebral hemorrhage , 2017, Neurology.

[10]  K. Melmed,et al.  Intracerebral Hemorrhagic Expansion Occurs in Patients Using Non-Vitamin K Antagonist Oral Anticoagulants Comparable with Patients Using Warfarin. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[11]  J. Marto,et al.  POST-NOAC: Portuguese observational study of intracranial hemorrhage on non-vitamin K antagonist oral anticoagulants , 2017, International journal of stroke : official journal of the International Stroke Society.

[12]  Y. Fujii,et al.  Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy. , 2016, American Journal of Cardiology.

[13]  D. Werring,et al.  Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type , 2016, Neurology.

[14]  H. Tomita,et al.  Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment: Comparison With Those During Warfarin , 2014, Stroke.

[15]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[16]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.